Navigation Links
Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
Date:9/3/2007

Publication in September issue of Nature Methods Shows Application of

Bioinformatics tools to Identify The Most Powerful Matrix Attachment

Regions Applied to Boost Transgene Expression.

GENEVA, Switzerland, Aug. 21 /PRNewswire/ -- Researchers at Selexis SA and The University of Lausanne have reported the identification of novel high-performance Genetic Elements also known as matrix attachment regions (or MARs). Data are presented using these novel high-performance Genetic Elements for increased gene expression in mammalian cells. This research, published online August 5 and in the September issue of the journal Nature Methods, demonstrates that using bioinformatics analysis, researchers computed putative novel genetic elements from the human genome and confirmed through cloning experiments that these newly identified genetic elements could significantly and stably increase transgene expression in mammalian cells when compared to previously known genetic elements.

"Having the ability to identify and apply the most powerful genetic elements for use in the rapid development of high-performance cell lines further improves our already powerful technology and service offering," said Dr. Igor Fisch, CEO of Selexis. "Selexis has been applying this experimental approach to identify of our most productive Selexis Genetic Elements, and in fact, we are planning the introduction of a new class of Selexis Genetic Elements later this year. These new elements will be smaller and more powerful and are showing even greater performance in boosting antibody expression in CHO cells," continued, Dr. Fisch. "We are confident our existing and new licensees and cell line development customers will benefit from this new offering."

About Selexis:

Selexis is a privately held biotechnology company dedicated to the development of innovative technologies and expert services to speed the development of high performance mammalian cell lines. The company's core intellectual property portfolio is based on the discovery and application of enabling genetic elements that control the dynamic organization of chromatin within all mammalian cells. Application of the Selexis Genetic Elements(TM) using the SURE Cell Line Development(SM) process has enabled the rapid development of high performance cell lines for a number of pharmaceutically important programs.

Selexis Genetic Elements(TM) and SURE Cell Line Development SM are trademarks of Selexis SA.


'/>"/>
SOURCE Selexis SA
Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. FDA Announces Series of Changes to the Class of Marketed Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
4. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
5. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
6. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
7. GlycoFi announces the first production of antibodies with human glycosylation in yeast
8. NHGRI announces new sequencing targets
9. CHAVI announces international search for genes affecting HIV response
10. NHGRI announces latest sequencing targets
11. MUHC announces a transplant first in Quebec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... ... November 12, 2019 , ... ... in the design and manufacturer of technical ergonomic seating solutions, announced this ... compliant with Healthier Hospital Initiative guidelines. Established by Practice Greenhealth, a health ...
(Date:11/12/2019)... , ... November 12, 2019 , ... ... for proposals from nonprofit U.S. universities and research institutions for its Instrumentation ... support of up to $1.2 million per site for the acquisition of instrumentation, ...
(Date:11/11/2019)... ... November 11, 2019 , ... MicroGenDX, ... played a key role in the award-winning study “Next Generation Sequencing for the ... The molecular diagnostic laboratory processed samples using Next Generation DNA Sequencing to examine ...
Breaking Biology News(10 mins):
(Date:11/9/2019)... ... November 08, 2019 , ... ... in pathology research, today announced the results of analyses examining the severity ... the phase 3 selonsertib studies (STELLAR). Strong correlations were demonstrated between AI-powered ...
(Date:11/5/2019)... ... November 05, 2019 , ... Focal ... CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By combining ... Fusion Bx 2.0 will give urologists across Europe the ability to perform targeted ...
(Date:11/2/2019)... , ... October 31, 2019 , ... ... by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise in biomedical ... tool allows researchers to quickly uncover relationships between genes, diseases, variants, phenotypes, and ...
(Date:10/29/2019)... ... October 29, 2019 , ... ... to announce its Silver sponsorship and cold chain validation workshop at the Biomanufacturing ... Pines in San Diego, California. , The Biomanufacturing World Summit brings ...
Breaking Biology Technology: